DOCSLIB.ORG

COVID-19 Publications - Week 23 2020 899 Publications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 Publications - Week 23 2020 899 Publications Update June 01- June 07, 2020, Dr. Peter J. Lansberg MD, PhD Weekly COVID-19 Literature Update will keep you up-to-date with all recent PubMed publications categorized by relevant topics COVID-19 publications - Week 23 2020 899 Publications PubMed based Covid-19 weekly literature update For those interested in receiving weekly updates click here For questions and requests for topics to add send an e-mail [email protected] Reliable on-line resources for Covid 19 WHO Cochrane Daily dashbord BMJ Country Guidance The Lancet Travel restriction New England Journal of Medicine Covid Counter JAMA Covid forcasts Cell CDC Science AHA Oxford Universtiy Press ESC Cambridge Univeristy Press EMEA Springer Nature Evidence EPPI Elsevier Wikipedia Wiley Cardionerds - COVID-19 PLOS Genomic epidemiology LitCovid NIH-NLM Oxygenation Ventilation toolkit SSRN (Pre-prints) German (ICU) bed capacity COVID reference (Steinhauser Verlag) COVID-19 Projections tracker AAN - Neurology resources COVID-19 resources (Harvard) COVID-19 resources (McMasters) COVID-19 resources (NHLBI) COVID-19 resources (MEDSCAPE) COVID-19 Diabetes (JDRF) COVID-19 TELEMEDICINE (BMJ) Global Causes of death (Johns Hopkins) Guidelines NICE Guidelines Covid-19 Korean CDC Covid-19 guidelines Flattening the curve - Korea IDSA COVID-19 Guidelines Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020) ESICM Ventilation Guidelines Performing Procedures on Patients With Known or Suspected COVID-19 (ASA, 2020) OSHA Guidance on Preparing the Workplace for COVID-19 (2020) Policy for Sterilizers, Disinfectant Devices, and Air Purifiers (FDA, 2020) Breast Cancer Patient Triage Guidelines (CPBCC, 2020) clinical guidance for adult Belgian patients with suspected or confirmed COVID-19 National Covid-19 Testing Action Plan (Rockefeller Foundation) ASE issues Echo-cardiography guidance Trials & Registries CAPACITY European registry COVID 19 patients WHO launches global megatrial FDA launches Convalescent plasma trial Lets Beat Covid-19 Survey to help plan hospital services COVID IBD registry Google mobility reports per country COVID 19 World's largest trial of potential coronavirus treatments rolled out across the UK Pregnancy Registry (US) ICNARC report on COVID-19 in critical care - NHS April 24 COVID-19 Human Genetics - Biobanks COVID19 settings of transmission database Mainstream Media Billionaire scientist’s COVID-19 vaccine selected for monkey tests(Science) How Iceland Beat the Coronavirus (New Yorker) Iran's rapid rise in Covid-19 cases stokes fears of the second wave (Guardian) Malaria Drug Did Not Prevent COVID Infections, Study Finds (NYT) Man Behind Sweden’s Controversial Virus Strategy Admits Mistakes (Bloomberg) Blood vessel attack could trigger coronavirus’ fatal ‘second phase’ (Science) Surgisphere: governments suspect data from tiny US company (Guardian) Genes May Leave Some People More Vulnerable to Severe Covid-19 (NYT) The pandemic's first major research scandal erupts (Science) The Lancet has made one of the biggest retractions in modern history (Guardian) Half of Coronavirus Spread May Traced to People Without Any Symptoms (TIMES) Coronavirus crowds out other research papers (Nature index) Important Mysteries About Coronavirus Endure (NYT) The search for a COVID-19 vaccine is gaining momentum (S. Diego Union Tribune) KeyArticles 1. COVID-19: the vasculature unleashed. Nat. Rev. Immunol. 2020; Teuwen LA, Geldhof V, Pasut A, Carmeliet P. http://www.ncbi.nlm.nih.gov/pubmed/? term=32439870 2. Cholesterol: A new game player accelerating endothelial injuries caused by SARS-CoV- 2? Am J Physiol Endocrinol Metab 2020; Cao X, Yin R, Albrecht H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32501731 3. The role of high cholesterol in age-related COVID19 lethality. bioRxiv preprint doi: https://doi.org/10.1101/2020.05.09.086249; Hao Wang, Zixuan Yuan, Mahmud Arif Pavel, Scott B. Hansen 4. Increasing Host Cellular Receptor-Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV (or SARS- CoV-2) Infection. J Med Virol 2020; Zhuang MW, Cheng Y, Zhang J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32497323 5. The immune system and COVID-19: Friend or foe? Life Sci 2020:117900Yazdanpanah F, Hamblin MR, Rezaei N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32502542 6. Endothelial cell infection and endotheliitis in COVID-19. The Lancet 2020; 395:1417-1418Varga Z, Flammer AJ, Steiger P et al. 7. Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. Clin Microbiol Infect 2020; Van Elslande J, Houben E, Depypere M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32473953 8. Approach to Acute Cardiovascular Complications in COVID-19 Infection. Circ Heart Fail 2020; Ranard LS, Fried JA, Abdalla M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32500721 9. Biomarkers associated with COVID-19 disease progression. Crit. Rev. Clin. Lab. Sci. 2020:1-11Ponti G, Maccaferri M, Ruini C et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32503382 10. Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement from the Cardiac Society of Australia and New Zealand (CSANZ). Heart Lung Circ. 2020; Nicholls SJ, Nelson M, Astley C et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32473781| 11. COVID-19 Related Coagulopathy: A Distinct Entity? J Clin Med 2020; 9Marchandot B, Sattler L, Jesel L et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=32486469 12. Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA). Vasa 2020:1-5Linnemann B, Bauersachs R, Grebe M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32501145 13. Renin-Angiotensin-System (RAS) and COVID-19 - On the Prescription of RAS Blockers. Deutsche Medizinische Wochenschrift 2020; 145:682- 686Kreutz R, Abd El-Hady Algharably E, Ganten D, Messerli F. 14. Association of hypertension and antihypertensive treatment with COVID- 19 mortality: a retrospective observational study. Eur Heart J 2020; Gao C, Cai Y, Zhang K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32498076 15. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020; 369:m1985Docherty AB, Harrison EM, Green CA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32444460 Basic Science (27 articles) 1. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany NY) 2020; 12Asselta R, Paraboschi EM, Mantovani A, Duga S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32501810 2. Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy 2020; Radzikowska U, Ding M, Tan G et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32496587 3. Related molecular mechanisms of COVID-19, hypertension, and diabetes. Am J Physiol Endocrinol Metab 2020; 318:E881Akkus E, Sahin M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32479159 4. S1 Subunit and Host Proteases as Potential Therapeutic Avenues for the Treatment of COVID-19. Arch Med Res 2020; Arafah A, Ali S, Yatoo AM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32493626 5. Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2. Arch Med Res 2020; Satarker S, Nampoothiri M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32493627 6. Effects of host genetic variations on response to, susceptibility and severity of respiratory infections. Biomed. Pharmacother. 2020; 128:110296Ghafouri-Fard S, Noroozi R, Vafaee R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32480226 7. Interaction of the prototypical alpha-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex. Comput. Biol. Chem. 2020; 87:107292Liang J, Pitsillou E, Karagiannis C et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32485652 8. COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice. Hum Genomics 2020; 14:20Lutz C, Maher L, Lee C, Kang W. http://www.ncbi.nlm.nih.gov/pubmed/? term=32498696 9. Human Gene Sequences in SARS-CoV-2 and Other Viruses. In Vivo 2020; 34:1633-1636Lehrer S, Rheinstein PH. http://www.ncbi.nlm.nih.gov/pubmed/?term=32503822 10. SARS-CoV-2 orf1b Gene Sequence in the NTNG1 Gene on Human Chromosome 1. In Vivo 2020; 34:1629-1632Lehrer S, Rheinstein PH. http://www.ncbi.nlm.nih.gov/pubmed/?term=32503821 11. Unfolding SARS-CoV-2 viral genome to understand its gene expression regulation. Infect Genet Evol 2020:104386Dinka H, Milkesa A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32473977 12. Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: A computational biology approach. Infect Genet Evol 2020:104389Lokman SM, Rasheduzzaman MD, Salauddin A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32502733 13. SARS-CoV-2 molecular and phylogenetic analysis in COVID-19 patients: A preliminary report from Iran. Infect Genet Evol 2020:104387Tabibzadeh A, Zamani F, Laali A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32485332 14. A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2. Int. J. Biol. Macromol. 2020; Wang M, Fu T, Hao J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32485251 15. Antiviral Effects of Probiotic metabolites on COVID-19. J Biomol Struct Dyn 2020:1-11Anwar F, Altayb HN, Al-Abbasi FA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=32475223 16. Virtual Screening-Driven Drug Discovery of SARS-CoV2 Enzyme Inhibitors Targeting Viral Attachment, Replication, Post-Translational Modification and Host Immunity Evasion Infection Mechanisms. J Biomol Struct Dyn 2020:1-23Quimque MTJ, Notarte KIR, Fernandez RAT et al.
Load more

Recommended publications
  • COVID-19 Situation Report 449
    For citation: Centre for Infectious Disease Epidemiology and Research-NUS. COVID-19 Situation Report 449. 23 April 2021 Apr 23 COVID-19 Situation Report 449 Centre for Infectious Disease Epidemiology and Research (CIDER) For citation: Centre for Infectious Disease Epidemiology and Research-NUS. COVID-19 Situation Report 449. 23 April 2021 i. Background In December, China notified the World Health Organization (WHO) of several cases of human respiratory illness, which appeared to be linked to an open seafood and livestock market in the city of Wuhan. The infecting agent has since been identified as a novel coronavirus, previously known as 2019-nCoV and now called SAR-CoV-2; The new name of the disease has also been termed COVID-19, as of 11th February 2020. Although the virus is presumed zoonotic in origin, person-to-person spread is evident. Screening of travellers, travel bans and quarantine measures are being implemented in many countries. Despite these precautions, it is anticipated that more cases will be seen both inside China and internationally. The WHO declared the outbreak of COVID-19 constitutes a Public Health Emergency of International Concern on 30 January. On 11 March, 2020, WHO declared the coronavirus outbreak a pandemic as the global death toll rose above 4,600 and the number of confirmed cases topped 125,000. This report aims to update Global Risk Assessment, Global Epidemiology, Quarantine Orders, Travel Ban/Advisory by countries, WHO’s and CDC’s Guidance and Protocols and Scientific publication on a daily basis. New updates in the tables are bolded. 1 | P a g e Centre for infectious di sease epidemiology and research For citation: Centre for Infectious Disease Epidemiology and Research-NUS.
    [Show full text]
  • An Update on Novel Approaches for Diagnosis and Treatment of SARS‑Cov‑2 Infection Azadeh Safarchi1*, Shadma Fatima1,2, Zahra Ayati3,4 and Fatemeh Vafaee1,5*
    Safarchi et al. Cell Biosci (2021) 11:164 https://doi.org/10.1186/s13578-021-00674-6 Cell & Bioscience REVIEW Open Access An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection Azadeh Safarchi1*, Shadma Fatima1,2, Zahra Ayati3,4 and Fatemeh Vafaee1,5* Abstract The ongoing pandemic of coronavirus disease 2019 (COVID-19) has made a serious public health and economic crisis worldwide which united global eforts to develop rapid, precise, and cost-efcient diagnostics, vaccines, and therapeutics. Numerous multi-disciplinary studies and techniques have been designed to investigate and develop various approaches to help frontline health workers, policymakers, and populations to overcome the disease. While these techniques have been reviewed within individual disciplines, it is now timely to provide a cross-disciplinary overview of novel diagnostic and therapeutic approaches summarizing complementary eforts across multiple felds of research and technology. Accordingly, we reviewed and summarized various advanced novel approaches used for diagnosis and treatment of COVID-19 to help researchers across diverse disciplines on their prioritization of resources for research and development and to give them better a picture of the latest techniques. These include artifcial intel- ligence, nano-based, CRISPR-based, and mass spectrometry technologies as well as neutralizing factors and traditional medicines. We also reviewed new approaches for vaccine development and developed a dashboard to provide frequent updates on the current and future approved vaccines. Keywords: COVID-19, SARS-COV-2, Diagnostics, Vaccines, Treatment Background envelope protein (E), membrane protein (M), and nucle- As of late June 2021, with over 180 million confrmed ocapsid protein (N) [2, 3].
    [Show full text]
  • 1/4/21 Summary Corona Virus Update by H. Robert Silverstein, MD, FACC for the Preventive Medicine Center
    1/4/21 Summary Corona Virus Update by H. Robert Silverstein, MD, FACC for the Preventive Medicine Center Clyde W. Yancy, MD, Vice Dean for Diversity and Inclusion Chief of Cardiology in the Department of Medicine, Feinberg School of Medicine at Northwestern University in Chicago Clyde W. Yancy, MD: “I’m exhausted by the stress; disheartened by the toll on human life; concerned deeply about the exposure to healthcare workers- BUT, I am emboldened by the display of courage, selflessness, compassion, and sacrifice that I see in physicians, nurses and health care workers across the country.” History, precedents, similarities, virus structure and invasion, pathology, physiology, lethality vs safety in perspective, China, geography, EU vs USA comparison, time-line, media, politics, pandemic modelling, symptoms, lockdown, economics, joblessness, vascular-platelet-glycocalyx clotting, testing, ventilators, medications, vaccines, supplements, diet: This 2019 corona virus CoV2-19 is an entirely new RNA virus with 30 proteins. Corona viruses have the largest known viral genome. The RNA of a corona virus is single-stranded. The word “VIRUS” means “poison.” A human cell has 20,000 different proteins. Being an RNA virus, it is similar to hepatitis C; it is not a DNA virus like hepatitis B. There are 200 viruses that can cause the common cold and several of these are corona viruses. “Corona” is Latin for “crown” which is how the virus looks in the microscope as if it has an encircling crown. The specific CoV2-19 1 genetic RNA fact and its “SPIKE” projections will affect anti-viral treatment design and decisions. That virus spike binds to and fuses with host cells.
    [Show full text]
  • HZS C2BRNE DIARY – January 2021
    1 HZS C2BRNE DIARY – January 2021 www.cbrne-terrorism-newsletter.com 2 HZS C2BRNE DIARY – January 2021 HZS C2BRNE DIARY– 2021© January 2021 Website: www.cbrne-terrorism-newsletter.com Editor-in-Chief BrigGEN (ret.) Ioannis Galatas MD, MSc, MC (Army) PhD cand Consultant in Allergy & Clinical Immunology Medical/Hospital CBRNE Planner & Instructor Senior Asymmetric Threats Analyst Manager, CBRN Knowledge Center @ International CBRNE Institute (BE) Senior CBRN Consultant @ HotZone Solutions Group (NL) Athens, Greece Contact e-mail: [email protected] Editorial Team ⚫ Bellanca Giada, MD, MSc (Italy) ⚫ Hopmeier Michael, BSc/MSc MechEngin (USA) ⚫ Kiourktsoglou George, BSc, Dipl, MSc, MBA, PhD (UK) ⚫ Photiou Steve, MD, MSc EmDisaster (Italy) ⚫ Tarlow Peter, PhD Sociol (USA) A publication of HotZone Solutions Group Prinsessegracht 6, 2514 AN, The Hague, The Netherlands T: +31 70 262 97 04, F: +31 (0) 87 784 68 26 E-mail: [email protected] DISCLAIMER: The HZS C2BRNE DIARY® (former CBRNE-Terrorism Newsletter), is a free online publication for the fellow civilian/military CBRNE First Responders worldwide. The Diary is a collection of papers/articles related to the stated thematology. Relevant sources/authors are included and all info provided herein is from open Internet sources. Opinions and comments from the Editor, the Editorial Team or the authors publishing in the Diary do not necessarily represent those of the HotZone Solutions Group (NL) or the International CBRNE Institute (BE). www.cbrne-terrorism-newsletter.com 3 HZS C2BRNE DIARY – January 2021 www.cbrne-terrorism-newsletter.com 4 HZS C2BRNE DIARY – January 2021 www.cbrne-terrorism-newsletter.com 5 HZS C2BRNE DIARY – January 2021 Editorial Brig Gen (ret.) Ioannis Galatas, MD, MSc, MC (Army) Editor-in-Chief HZS C2BRNE Diary Dear Colleagues, New Year, Blank Page? effects and duration of effectiveness of vaccination.
    [Show full text]
  • GJE Volume 5, Special Issue
    Volume 5, Special Issue Number 1 Print ISSN: 2574-0415 Online ISSN: 2574-0423 GLOBAL JOURNAL OF ENTREPRENEURSHIP 2021 SPECIAL ISSUE Building Business Resilience and Sustainability Special Issue Co-Editors: Victor S. Sohmen Harrisburg University of Science and Technology, PA Denise Siegfeldt Florida Institute of Technology, FL Marvin Ludlum University of Central Oklahoma, OK The Global Journal of Entrepreneurship is owned and published by the Institute for Global Business Research. Editorial content is at the discretion of the Institute for Global Business Research, which is dedicated to the advancement of learning and scholarly research in all areas of business. Global Journal of Entrepreneurship Vol. 5 (Special Issue) No. 1, 2021 Authors execute a publication permission agreement and assume all liabilities. The Institute for Global Business Research is not responsible for the content of the individual manuscripts. Any omissions or errors are the sole responsibility of the authors. The Editorial Review Board is responsible for the selection and review of manuscripts for publication from among those submitted for consideration. The Publishers accept final manuscripts in digital form and make adjustments solely for the purposes of pagination and organization. The Global Journal of Entrepreneurship is owned and published by the Institute for Global Business Research, 1 University Park Drive, Nashville, TN 37204- 3951 USA. Those interested in communicating regarding the Journal, should contact the Executive Director of the Institute for Global
    [Show full text]
  • Investors Search for a Winner in the Vaccine Race
    Investors search for a winner in the vaccine race It’s not just about who’s first, but about who can deliver The race to develop a COVID-19 coronavirus vaccine is on. There are literally around 100 companies globally as well as numerous government organizations all rushing to get an effective and safe COVID-19 vaccine approved and ready for widespread use. After developing a vaccine comes testing (including 3 phases of human trials with bigger numbers in each phase), then FDA approval in the U.S., and finally production. Normally this process can take up to 10 years, but with the personal and global economic challenges of COVID-19, the goal is to have an effective and safe vaccine in 1-2 years, with the leading companies now moving into phase 3 human trials. For investors the key question is which companies will win the race to produce a safe and effective vaccine, stopping the pandemic and allowing the global economy to return to some form of normality. Certainly with global cases at a staggering 20,810,774 and 746,411 deaths, the world desperately needs a cure. Worst hit countries are currently the USA, Brazil and India. Cumulative global COVID-19 cases by country as of August 12, 2020 Source: www.worldometers.info Today I look at which countries and companies are leading the COVID-19 vaccine race to see what may happen next. Russia The world’s press lit up this past week with Russia’s President Putin’s statement that Russia hasregistered the world’s first Covid-19 vaccine, named ‘Sputnik V’.
    [Show full text]
  • COVID-19 Health System Response Monitor Singapore
    COVID-19 Health System Response Monitor Singapore February 2021 Updated July 2021 Author Jacinta I‐Pei Chen Khin Chaw Ko Amelia Yamato Leow Mei‐li Jason CH Yap Jeremy Lim Chapter 7 update in July 2021 : Nikita Kanumoory Mandyam Jeremy Lim All the authors are from the Saw Swee Hock School of Public Health, National University of Singapore World Health Organization Regional Office for South‐East Asia COVID‐19 health system response monitor: Singapore ISBN 978‐92‐9022‐852‐3 © World Health Organization 2021 (on behalf of the Asia Pacific Observatory on Health Systems and Policies) Some rights reserved. This work is available under the Creative Commons Attribution Non‐Commercial Share Alike 3.0 IGO licence (CC BY‐NC‐SA. 3.0 IGO. https://creativecommons.org/licenses/by‐nc‐sa/3.0/igo/). Under the terms of this licence, you may copy, redistribute and adopt the work for non‐commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adopt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition.” Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int.amc/en/mediation.rules).
    [Show full text]
  • List of Coronavirus Spirits for MD Abdominal Pain, Abnormal Clotting
    List of Coronavirus Spirits for MD Abdominal pain, abnormal clotting, abnormal heartbeat, abnormal heart function, abnormal kidney function, abnormal liver function, abuse of elderly, activation immunotherapies, Acute cardiac injury, Acute infections, Acute kidney injury, acute myocardial injury, Acute respiratory distress syndrome, ARDS, acute stress response, Adenovirus infection, aerosol transmission, African American people more susseptable, air transmission, Airborne Infection Isolation Room, alcohol abuse, alcohol addiction, alcoholism, Alphacoronavirus, ambu bag, aminotransferases, anemic, animal to human coronavirus diseases, animal to human transmission, anosmia, anticoagulant therapy, antiviral drugs, anxiety, arrhythmias, asymptomatic, Avian coronavirus, avian infectious bronchitis, azithromycin, bankrupsies, barking cough, behaviour problems, Beluga whale coronavirus, Betacoronavirus, bevacizumab, bi-level positive airway pressure, binge drinking, Biological therapy, bird flu, black people more susseptable, bleeding lungs, blood clots within the body, Blood vessel dysfunction, bloody flux, blue face, blue lips, body fluid transmission, boredom, bovine coronavirus, Bradykinin hypothesis, brain fog, brain inflammation, brain signals changed, bronchoalveolar washing, bronchitis, Bronchiolitis, Bulbul coronavirus, Buldecovirus, businesses shut down or closing, C30 Endopeptidase, cabin fever, cancelled resussitation orders, cardiac arrest, Cardiovascular complications, cardiovascular disease, cardiovascular symptoms, Cegacovirus,
    [Show full text]
  • Fortum Sustainability 2020
    Sustainability 2020 SUSTAINABILITY AT FORTUM CLIMATE AND RESOURCES PERSONNEL AND SOCIETY APPENDICES 2 Highlights 2020 New, ambitious safety target Coal-exit proceeding well; Employee engagement measured as TRIF* for own Uniper coal-fired power plant increased; personnel feels well personnel and contractors Heyden 4 taken out informed and supported during of commercial power the Covid-19 pandemic <1.0 generation at the end of 2020 by the end of 2025 * Total Recordable Injury Frequency Annual outage at Loviisa nuclear Increased capacity and power plant successfully competence in EV battery completed, with nearly 1,500 recycling workers from 10 different countries and no Covid-19 cases Uniper transaction successfully New corporate strategy New Corporate Social Up to completed and Uniper included as released; a Group-wide carbon Responsibility a subsidiary in Fortum’s reporting neutrality target, in line with programme launched the goals of the Paris Agreement, with strategic focus 70% by 2050 at the latest of new growth investments in 2021–2025 targeted at solar and wind power as well as hydrogen SUSTAINABILITY AT FORTUM CLIMATE AND RESOURCES PERSONNEL AND SOCIETY APPENDICES 3 Sustainability 2020 Highlights 2020 �����������������������������������������������������������������������������������������������2 Personnel and society ...........................................................................................53 Notes: Table of contents ������������������������������������������������������������������������������������������������������������3
    [Show full text]
  • 7/20/21 Summary Corona Virus Update by H. Robert Silverstein, MD, FACC for the Preventive Medicine Center
    7/20/21 Summary Corona Virus Update by H. Robert Silverstein, MD, FACC for the Preventive Medicine Center Clyde W. Yancy, MD, Vice Dean for Diversity and Inclusion Chief of Cardiology in the Department of Medicine, Feinberg School of Medicine at Northwestern University in Chicago Clyde W. Yancy, MD: “I’m exhausted by the stress; disheartened by the toll on human life; concerned deeply about the exposure to healthcare workers- BUT, I am emboldened by the display of courage, selflessness, compassion, and sacrifice that I see in physicians, nurses and health care workers across the country.” “It is not a case of ‘don’t confuse me with the facts’, but the best clinical insights exceed so called knowledge by at least one step.” “Early 2020 saw the world break into what has been described as a "war-like situation": A pandemic, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), the likes of which majority of the living generations across most of the planet have not ever seen. This pandemic has downed economies and resulted in hundreds of thousands of deaths.” Tokyo University of Science 7/1/21 1 History, precedents, similarities, virus structure and invasion, pathology, physiology, lethality vs safety in perspective, China, geography, EU vs USA comparison, time-line, media, politics, pandemic modelling, symptoms, lockdown, economics, joblessness, vascular-platelet-glycocalyx clotting, testing, ventilators, medications, vaccines, supplements, diet: This 2019 corona virus CoV2-19 is an entirely new RNA virus with 30 proteins. Corona viruses have the largest known viral genome. The RNA of a corona virus is single-stranded.
    [Show full text]
  • Dentons Flashpoint Daily Global Situation Report
    Dentons Flashpoint Daily Global Situation Report May 25, 2021 Global Situation Update: May 25, 2021 KEY TAKEAWAYS A US official expects The WHO reports that Malian military strong backing from only 1.5 percent of detained the G7 peers for proposed worldwide vaccine president and prime 15 percent-plus doses have been minister in a global minimum administered in Africa. potential coup. corporate tax. Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same. Global Situation Update: May 25, 2021 WHAT WE’RE WATCHING Moscow Today, rallies, marches, and other memorial events will be held across the US to mark the one-year anniversary of the death of George Floyd at the hands of police officer Derek Chauvin. President Spain Biden will host Floyd’s family at the White House. UAE While the conviction of Chauvin in April was welcomed by protestors, they will continue to push for justice in several other killings by police that have recently made domestic headlines. There is also a chance that peaceful protests today in Portland, Seattle, Miami, Minneapolis and elsewhere may be disrupted by armed white nationalist groups or confronted by police if they get out of control. Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same. Global Globally, confirmed coronavirus cases surpassed 167.2 million with 3.4 million deaths. • The US called for international experts to be allowed • Young children under the age of 12 are both to evaluate the source of the coronavirus and the susceptible to and significant carriers of more "early days of the outbreak" in a second phase of an transmissible coronavirus variants, according to a investigation into the origins of the coronavirus.
    [Show full text]
  • Visitor Demand Mapping Demand Visitor for Queenstown for Published on Wednesday, June 17, 2020 Update 2
    Visitor Demand Mapping for Queenstown Update 2 Published on Wednesday, June 17, 2020 1 | Visitor Demand Mapping for Queenstown Visitor 1 | This is an update to the Visitor Demand Mapping for Queenstown-Lakes (2020 to 2024) report published on Thursday, May 14, 2020. You can get the full version of the earlier report here. Recent developments to factors that impact visitation to Queenstown New Zealand economy New Zealand moved to Alert level one effective midnight 9th June. High frequency indicators of economic activity have remained steady over the past two weeks (exhibit 1), tracking slightly below the same period in 2019 . However, total spend has tracked slightly above the same period last year, with a 2% increase in spend vs same week prior year recorded, with industries such as repair services, home and recreational retailing and food and liquor driving the change, likely the “revenge” buying trend1 . While life in New Zealand maybe returning to “normal” in many ways there is no denying the ramifications of COVID-19 will be felt for many years. The Reserve Bank of New Zealand estimates 2020 will see the biggest drop in GDP in at least 160 years and the IMF is forecasting a -7.2% contraction in GDP growth in 2020 with the majority of this expected to fall in Q2, 20202. The labour market is likely to be particularly effected with the wage subsidy due to end on the 1st of September. This has the potential to cause a second wave of redundancies and the industries that have been hardest hit are also some of the most labour intensive3 (exhibit 2).
    [Show full text]